Literature DB >> 3696841

Epidemiologic markers of pediatric infections caused by coagulase-negative staphylococci.

W M Dunne1, D B Nelson, M J Chusid.   

Abstract

Several epidemiologic markers (species, slime production and antimicrobial susceptibility) were examined for 256 isolates of coagulase-negative staphylococci (C-S) obtained from clinical specimens in a 1-year period. The medical records of the 169 pediatric patients from whom the C-S were obtained were reviewed and divided into infected (N = 11) and uninfected (N = 158) groups. The phenotypic traits of strains associated with infection included: (1) slime production (P = 0.014); (2) slime-positive Staphylococcus epidermidis (P = 0.002); and (3) resistance to penicillin (P = 0.03), oxacillin (P less than 0.001), clindamycin (P = 0.003), chloramphenicol (P less than 0.001) and trimethoprim/sulfamethoxazole (P less than 0.001). Infected patients were significantly older (P = 0.006) than uninfected patients. Simultaneous isolation of the same strain of C-S from the aerobic and anaerobic bottles of a single blood culture increased the probability of sepsis (P = 0.004). The combination of these patient and laboratory data may be useful in determining the clinical significance of C-S recovered from pediatric patients.

Entities:  

Mesh:

Year:  1987        PMID: 3696841

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  12 in total

1.  Adherence measured by microtiter assay as a virulence marker for Staphylococcus epidermidis infections.

Authors:  M A Deighton; B Balkau
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

2.  In vitro measurement of the adherence of Staphylococcus epidermidis to plastic by using cellular urease as a marker.

Authors:  W M Dunne; E M Burd
Journal:  Appl Environ Microbiol       Date:  1991-03       Impact factor: 4.792

3.  Effects of subinhibitory concentrations of vancomycin or cefamandole on biofilm production by coagulase-negative staphylococci.

Authors:  W M Dunne
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  The ica operon and biofilm production in coagulase-negative Staphylococci associated with carriage and disease in a neonatal intensive care unit.

Authors:  G D I de Silva; M Kantzanou; A Justice; R C Massey; A R Wilkinson; N P J Day; S J Peacock
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Production of extra-cellular slime by Staphylococcus epidermidis during stationary phase of growth: its association with adherence to implantable devices.

Authors:  R Bayston; J Rodgers
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

Review 6.  Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci.

Authors:  M A Pfaller; L A Herwaldt
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

7.  Characterization of transposon mutants of biofilm-producing Staphylococcus epidermidis impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesin.

Authors:  D Mack; M Nedelmann; A Krokotsch; A Schwarzkopf; J Heesemann; R Laufs
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Regulation of slime production in Staphylococcus epidermidis by iron limitation.

Authors:  M Deighton; R Borland
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Association of coagulase-negative staphylococcal slime production and adherence with the development and outcome of adult septicemias.

Authors:  P Kotilainen
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

10.  The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis.

Authors:  D Mack; W Fischer; A Krokotsch; K Leopold; R Hartmann; H Egge; R Laufs
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.